Two GREAT takeaways, page-6

Love your work Yankee

but just to be clear ... MSB's RA treatment may obtain regenerative advanced therapy designation which would fast track approval ... but this in my mind does not mean it will obtain approval on phase 2 data.. instead it will still run a phase 3, but will be accelerated through the process (priority consultation with FDA, streamlined filing and priority review).

Happy to be corrected - but that is my take on it.

On that point, given the significant efficacy shown by MSB's MPC 300 IV - the powering would mean that a sample of a few hundred patients would be sufficient.. rather than thousands. This would be a quick phase 3 trial and relatively cheap.

Partnership by the end of 2017 is more likely than not for RA ... and with MNK lined up, we could end the year with two partners ... and CHF still on the table (read-out coming out in the next couple of months). Who knows.. maybe three partners!

My guess is that MESO will scream overnight in the US, and the ASX will have no choice but to follow. The significance of this announcement is worth much more than a 3.77% increase in SP ...